Aldeyra Therapeutics Says 'Due to Shortage of Methotrexate, Lack of Approved Therapy for PVRL, and Inbound Requests for ADX-2191, Expanded Access Program Planned to be Discussed with FDA'
Portfolio Pulse from Bill Haddad
Aldeyra Therapeutics plans to discuss an Expanded Access Program with the FDA due to a shortage of Methotrexate, lack of approved therapy for PVRL, and inbound requests for ADX-2191.
June 21, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aldeyra Therapeutics' stock may be impacted by the company's plan to discuss an Expanded Access Program with the FDA for ADX-2191.
The news of Aldeyra Therapeutics discussing an Expanded Access Program with the FDA for ADX-2191 is directly related to the company and its product pipeline. This could potentially lead to increased demand for ADX-2191 and positively impact the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100